Supplementary Data from Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)
Abstract
Supplementary Data from Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin LymphomaKeywords
This publication has 0 references indexed in Scilit: